1.LU Fang's Clinical Experience in Differentiation and Treatment of Systemic Lupus Erythematosus from the Perspective of Heat-Toxin and Blood-Stasis in the Collaterals
Yingchao NIU ; Yongzhu PIAO ; Xiang GENG ; Zhihui GAO ; Yan ZHANG ; Huibin WU ; Zhilong WANG ; Shuangshuang GE ;
Journal of Traditional Chinese Medicine 2026;67(1):16-20
This paper summarizes Professor LU Fang's clinical experience in treating systemic lupus erythematosus (SLE) based on the differentiation and treatment of heat-toxin and blood-stasis in the collaterals. SLE is generally characterized by deficiency in origin with excess in manifestation. The core pathogenesis is heat-toxin obstructing the collaterals. During the acute active stage, the predominant pattern is blazing heat-toxin causing blood stasis, while in the chronic remitting stage, the main pattern is toxic stasis blocking the collaterals with qi and yin deficiency. Clinical treatment follows the basic principle that treat with salty-cold herbs, when heat invades internally and that assist with acrid-dispersing herbs when stasis obstructs the collaterals. The self-formulated Yimian Decoction (抑免汤) serves as the base formula and is applied in stages. During the acute active stage, it is often combined with herbs for clearing heat and detoxifying, cooling blood and resolving stasis, and unblocking the collaterals. In the chronic remitting stage, it is often combined with herbs for activating blood circulation and unblocking the collaterals, as well as tonifying qi and nourishing yin.
2.History and prospects of the military hospital preparation rooms
Jianping WANG ; Zhihui YANG ; Bo DAI ; Qing SONG
Journal of Pharmaceutical Practice and Service 2026;44(2):108-112
Military hospital preparation rooms are an important part of military medical institutions and have played an important role in military pharmacy support in history. However, with the development of science and technology, the improvement of domestic pharmaceutical production and innovation capabilities, and the adjustment of the military establishment and system, the establishment structure, functional tasks, and business forms of military medical institutions have undergone significant changes. The historical evolution of military preparation rooms were reviewed, the current situation were analyzed and the development challenges faced were identified. It was also explored how military hospital preparation rooms, as an important link in military pharmaceutical support, can face new situations and adapt to new forms of warfare. By enhancing the military efficiency of preparation rooms, it could play a greater role in improving medical support capabilities and enhancing the combat effectiveness of troops.
3.Pathogenesis Evolution and Staged Differentiation and Treatment Strategy of Atherosclerotic Plaques:from the Perspective of "Constraint-Putrefaction-Ulceration"
Hanzheng WANG ; Zhihui LIU ; Hanlu CHEN ; Yilei KONG ; Aisong ZHU
Journal of Traditional Chinese Medicine 2026;67(11):1162-1166
Atherosclerotic plaques arise within the vessels, yet their morphological evolution parallels that of carbuncles and abscesses. Drawing on the pathomechanism progression of carbuncles and abscesses, this paper proposes a dynamic pathogenesis model of "constraint-putrefaction-ulceration" for atherosclerotic plaques. The formation of atherosclerotic plaque begins with phlegm-turbidity obstruction and qi-blood stagnation (constraint stage); prolonged constraint transforms into heat that scorches the vessels and forms plaques (putrefaction stage); ultimately, toxin invades inward and ruptures the vessels, injuring the heart (ulceration stage). Accordingly, staged differentiation and treatments are proposed. During the constraint stage, the focus is venting constraint and unblocking collaterals, clearing and relieving constraint-heat, for which Yue Jyu Pills (越鞠丸) and Danzhi Xiaoyao Powder (丹栀逍遥散) with modifications can be used. During the putrefaction stage, the method is clearing heat and dispelling abscesses, resolving stasis and dissipating knot, with modified Wuwei Xiaodu Beverage (五味消毒饮) and Xuefu Zhuyu Decoction (血府逐瘀汤). During the ulceration stage, it is suggested to expell toxin and stasis, benefit qi and nourish yin using modified Gualou Xiebai Banxia Decoction (瓜蒌薤白半夏汤) and Sheng Mai Powder (生脉散). This framework offers new perspectives for the differentiation and treatment of atherosclerotic plaques in traditional Chinese medicine.
4.Identification and content determination of active components in Shugantongluo capsules
Bo DAI ; Fang WANG ; Fangchu XU ; Min ZHOU ; Hailong YUAN ; Zhihui YANG
Journal of Pharmaceutical Practice and Service 2026;44(7):358-361
Objective To establish the method of thin layer chromatography (TLC) for identification and content quantitative determination of Shugantongluo capsules, and provide methodological reference for the quality control of Shugantongluo capsules. Methods Bupleuriradix, polygala tenuifolia yuanzhi, and acorus tatarinowii rhizoma were identified by TLC qualitatively. The content of Saikosaponin-a was determined by HPLC method. The chromatography was performed on Venusil XBP C18(L) (4.6 mm×150 mm, 5 μm) with a stable temperature of 30℃. The mobile phase in isocratic elution consisted of acetonitrile-water (40∶60, V/V) at the flow rate of 1.0 ml/min with an injection volume of 20 μl. The detection wavelength was set at 210 nm. Results Clear spots were obtained with good separation in TLC identification which was highly specific. The Saikosaponin-a at the range of 25.00-500.0 μg/ml was linear with peak area (r=0.999 9), the average recovery rate was 97.00%, and RSD was 2.60%. Conclusion These methods was easy to operate with accurate results, with good specificity and reproducibility, which could be uesd for the quality control for Shugantongluo capsules.
5.Quality control standards for biological specimens from patients with oral and maxillofacial tumors
CHEN Wantao ; PAN Xinhua ; HE Yue ; YAN Ming ; WANG Lizhen ; WANG Yan&rsquo ; an ; LI Siyi ; LI Zhihui ; ZHANG Zhen ; DU Mengxuan
Journal of Prevention and Treatment for Stomatological Diseases 2026;34(9):833-842
Quality control (QC) of biospecimens from oral and maxillofacial tumors patients constitutes a critical foundation for the prevention, diagnosis, treatment, and precision medicine research of these diseases. Biospecimen quality directly governs the discovery and validation of disease biomarkers, the elucidation of pathogenesis, and the efficacy of clinical translation. QC spans the entire biospecimen lifecycle—encompassing collection, processing, storage, transportation, and utilization. Its primary objectives are to ensure sample integrity, reliability, traceability, and consistency, thereby guaranteeing the robustness of research data; the accuracy of molecular subtyping, biomarker identification, and treatment response prediction; and the precision of clinical decision-making. However, current QC frameworks for these biospecimens remain underdeveloped. Drawing on domestic and international technical standards, regulatory guidelines, and recent research advances, this paper elaborates on the importance of implementing a QC management system throughout the biospecimen lifecycle. It focuses on QC methodologies tailored to diverse biospecimen types, examining how standardized sampling procedures, regulated preprocessing workflows, and optimized long-term storage conditions influence sample quality. We aim to provide concrete guidance and a transferable paradigm for establishing standardized QC protocols and an informatics-enabled traceability system specific to oral and maxillofacial tumors. Such efforts are intended to enhance the research value and clinical utility of these biospecimens, furnishing reliable sample resources and technical support for the development of precision diagnostics and therapeutics. Furthermore, we advocate for a dual-track “QC plus Ethics” management framework within biobanks. This approach would reinforce ethical and legal safeguards, establishing a robust barrier to support safe scientific innovation and clinical translation.
6.Clinical Significance of Decreased Serum IgA Levels in IgG4-Related Disease
Xia ZHANG ; Yuetong XU ; Difei LIAN ; Zhihui WANG ; Hang ZHOU ; Fan YANG ; Yanying LIU
JOURNAL OF RARE DISEASES 2026;5(3):292-302
To explore the clinical significance of decreased serum immunoglobulin (Ig) A levels in patients with IgG4-related disease (IgG4-RD). A retrospective analysis was performed on patients with IgG4-RD hospitalized at Beijing Friendship Hospital, Capital Medical University from January 2012 to December 2024. Patients were divided into three groups according to serum IgA levels: decreased IgA group (< 70 mg/dL), normal group (70-400 mg/dL), and elevated group (> 400 mg/dL), with the decreased IgA group set as the main research subject. Clinical data were collected to compare clinical characteristics and organ involvement among the three groups, and the correlations between IgA levels and various clinical indicators were analyzed. To further verify the robustness of the results, propensity score matching(PSM) with a 1∶2 matching ratio was performed between the decreased IgA group and the normal IgA group for sensitivity analysis. Meanwhile, principal component analysis (PCA) was used to evaluate the overall distribution differences in clinical characteristics among the three groups with different IgA levels. A total of 330 patients with IgG4-RD were included, including 14 in the decreased IgA group, 297 in the normal IgA group, and 19 in the elevated IgA group. The decreased IgA group had a significantly longer median disease course than the normal IgA group and the elevated IgA group (all Decreased IgA level represents a distinct immune subtype of IgG4-RD, with distinct immunological features (elevated IgG/IgG4 levels, reduced C4 level, and increased EOS count), independent of age, gender and disease course. These findings suggest that serum IgA level has potential value for immune typing of IgG4-RD.
7.Evidence-based progress and clinical enlightenment of low-dose colchicine in secondary prevention of atherosclerotic cardiovascular disease
Xianghong WANG ; Jinxia ZHANG ; Rui LI ; Ge GUAN ; Xue GONG ; Mengmiao ZHANG ; Bo JI ; Jian LI ; Zhihui JIANG
China Pharmacy 2026;37(19):2608-2614
Residual inflammatory risk (RIR) is a key issue to be urgently addressed in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Targeted intervention of RIR has become a novel target for drug development and clinical management. A series of high-quality randomized controlled trials (RCTs), including COLCOT, LoDoCo2 and CLEAR SYNERGY, provided high-level evidence and confirmed that low-dose colchicine (0.5 mg/d) significantly reduced the risk of cardiovascular events in ASCVD patients at stable stage or after the acute phase, while its efficacy varied in different clinical scenarios. International authoritative guidelines from the European Society of Cardiology and the American Heart Association/American College of Cardiology include low-dose colchicine in the recommendations for ASCVD secondary prevention. Two domestic guidelines released in 2024, namely the Guideline for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndrome ( 2024 ) and the Guideline for the Diagnosis and Management of Chronic Coronary Syndrome in China , have also added relevant recommendations. Nevertheless, due to potential racial differences, safety concerns regarding drug-drug interactions, and the relative lack of clinical evidence in China, especially the absence of prospective RCTs using low-dose colchicine for secondary prevention of ASCVD patients, current clinical recommendations still mainly based on international evidence and guidelines, and should not be simply extrapolated.
8.Cyclocarya paliurus Polysaccharide Inhibits Benign Prostatic Hyperplasia by Reducing 5α-Reductase 2
Qinhui DAI ; Mengxia YAN ; Chen WANG ; Chenjun SHEN ; Chenying JIANG ; Bo YANG ; Huajun ZHAO ; Zhihui ZHU
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(3):107-114
ObjectiveTo investigate the effect and mechanism of polysaccharide in water extract of Cyclocarya paliurus (CPWP) in inhibiting benign prostatic hyperplasia (BPH). MethodsCPWP was obtained by heating reflux, aqueous extraction, alcohol precipitation, and freeze drying. The chemical composition and structural properties of CPWP were analyzed by high performance liquid chromatography with 1-pheny-3-methyl-5-pyrazolone pre-column derivatization and infrared spectroscopy. Male SD rats were randomly assigned into control, model, finasteride (ig 5 mg·kg-1), and low-, medium-, and high-dose (ig 50, 75, 100 mg·kg-1) CPWP groups, with 8 rats in each group. The BPH model was established by subcutaneously injecting propionate testosterone in castrated rats. The rats in the drug intervention groups were administrated with corresponding drugs, and those in the control group were administrated with an equal volume of normal saline each day. After 30 consecutive days, the rats were sacrificed, and the prostate tissue was separated and weighed. The effects of drug interventions on the body weight, prostate wet weight, and prostate index of rats were examined. The prostate tissue was stained with hematoxylin-eosin (HE) for observation of pathological changes. Enzyme-linked immunosorbent assay was employed to measure the level of dihydrotestosterone (DHT), and immunohistochemical staining was used to detect the expression of steroid 5 alpha-reductase 2 (SRD5A2) and Ki67 in the prostate tissue. ResultsCPWP was identified as a saccharide, with characteristic absorption peaks of saccharides. CPWP showed the total sugar content of 44.15% and molecular weight within the range of 5.5-78.8 kDa, being composed of mannose, rhamnose, galacturonic acid, glucose, galactose, xylose, and arabinose. Compared with the control group, the model group had significantly increased prostate wet weight and prostate index (P<0.01), thick and tall prostate epithelial cells, increased internal wrinkles, papillary expansion into the cavity, an elevation in DHT level in the serum, and up-regulated expression of SRD5A2 and Ki67 in the prostate tissue (P<0.05, P<0.01). Compared with the model group, both the finasteride and CPWP groups showed decreases in prostate wet weight and prostate index (P<0.05, P<0.01), thinned prostate epithelial cells, with only a small portion of internal wrinkles and papillary expansion into the cavity, shortened papillary protrusions, lowered DHT level in the serum, and down-regulated expression of SRD5A2 and Ki67 in the prostate tissue (P<0.01). Moreover, CPWP exerted effects in a dose-dependent manner. ConclusionCPWP inhibits BPH by regulating the expression of SRD5A2.
9.Modified electroconvulsive therapy for Alzheimer's disease: a two-case report
Sichuan Mental Health 2025;38(5):465-468
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by progressive cognitive decline and commonly accompanied by agitation and aggressive behaviors. Conventional pharmaceutical treatments, such as antipsychotics, often provide limited therapeutic benefits and pose considerable risks of adverse effects. Modified electroconvulsive therapy (MECT), a refined adaptation of electroconvulsive therapy, has been widely utilized in the treatment of mental disorders. This article reported the treatment of agitation and aggressive behavior disorders in one AD patient and one patient with schizophrenia comorbid AD. Combined with relevant domestic and foreign research, it analyzed the potential role of MECT in improving behavioral disorders in AD patients, aiming to provide clinical references for formulating MECT treatment plans for AD.
10.Meta-analysis of influencing factors for ART discontinuation in Chinese HIV/AIDS patients
Sihui LIN ; Lianzhao YANG ; Xiuhong LONG ; Tian FENG ; Zhihui WANG ; Yunfan YANG ; Aihong MING
Chongqing Medicine 2025;54(6):1435-1441
Objective To systematically evaluate the influencing factors for antiretroviral therapy(ART)discontinuation in Chinese human immunodeficiency virus(HIV)/acquired immuno deficiency syn-drome(AIDS)patients.Methods A computer-based search was conducted in PubMed,Web of Science,Em-base,The Cochrane Library,CNKI,Wanfang,VIP,and China Biology Medicine(CBM)databases for studies on influencing factors of ART discontinuation in Chinese HIV/AIDS patients from the establishment of the databases to August 2024.Meta-analysis was performed on the included studies by using Stata16.0.Results A total of 17 studies were included.Meta-analysis showed that the following factors were associated with ART discontinuation:male gender(OR=1.301,95%CI:1.099-1.540),age≥50 years(OR=1.212,95%CI:1.109-1.324),unmarried/divorced/widowed marital status(OR=1.198,95%CI:1.060-1.354),education level was or below senior high school(OR=1.778,95%CI:1.508-2.096),infection route was in-travenous drug use(OR=2.420,95%CI:1.989-2.945),baseline CD4 cell count>500 cells/μL(OR=1.157,95%CI:1.020-1.313),tuberculosis co-infection before ART(OR=1.559,95%CI:1.398-1.739),hepatitis B co-infection before ART(OR=1.554,95%CI:1.305-1.851),AIDS-related symptoms occur be-fore ART(OR=1.245,95%CI:1.148-1.351),time from diagnosis to treatment initiation≥365 days(OR=1.449,95%CI:1.301-1.615),initial treatment regimen containing zidovudine(OR=1.573,95%CI:1.206-2.052),treatment at county-level or lower institutions(OR=1.204,95%CI:1.153-1.257),exist drug adverse reactions(OR=7.043,95%CI:3.142-15.786),and compliance education(OR=0.182,95%CI:0.094-0.352).Conclusion There are multiple factors influencing ART discontinuation in Chinese HIV/AIDS patients.Early identification of individuals at risk of discontinuation and targeted interventions are nec-essary to promote their maintenance of ART.


Result Analysis
Print
Save
E-mail